Skip to main content
Clinical Trials/NCT04625088
NCT04625088
Completed
Not Applicable

Identification of Biometric Marker(s) Capable of Detecting Early Prediabetes: Clinical Trial 1: Antagonism of Hepatic Muscarinic Receptors Attenuates the Postprandial Actions of Hepatic Insulin Sensitizing Substance (HISS)

SciMar Ltd.1 site in 1 country24 target enrollmentMarch 1, 2021

Overview

Phase
Not Applicable
Intervention
Standardized liquid test meal
Conditions
Healthy
Sponsor
SciMar Ltd.
Enrollment
24
Locations
1
Primary Endpoint
Time course change in serum glucose
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The proposed clinical trial is a controlled study of n=24 healthy adult individuals tested in both the Meal-Induced Insulin Sensitization (MIS) state and, following atropine blockade, Absence of Meal-Induced Insulin Sensitization (AMIS) state to differentiate the postprandial glycemia, insulinemia, triglyceride and Hepatic Insulin Sensitizing Substance (HISS) levels in the two states.

The purpose of this study is the identification and development of biometric markers which incorporate the actions and interplay between insulin and HISS. Overall, the study aims to:

  1. Utilize a standardized test meal to detect one of the earliest pathologies present during the development of insulin resistance, pre-diabetes and obesity.
  2. Compare the control (HISS positive) and post-atropine (HISS negative) tests with the acute consequences of absence of MIS (AMIS) being graphically shown over 4 hours of postprandial nutrient partitioning, tracking the full metabolomic dynamic pattern.
  3. To establish values for potential indices (bio-impedance, hand-grip strength, spirometry) in young, fit, lean individuals. These values will be used as baselines for comparative analysis in future clinical trials employing individuals with various degrees of insulin resistance to full Type 2 Diabetes.
  4. Demonstrate that these biometric markers can differentiate between the HISS positive and HISS negative post-meal state with the future aim of using the biomarkers for the detection of early prediabetes.

The study will involve 4 study visits: Visit 1 - Prescreening; Visit 2 - Screening; Visit 3 - Liquid test meal administration and postprandial blood collection; Visit 4 - Atropine administration + Liquid test meal administration and postprandial blood collection.

Registry
clinicaltrials.gov
Start Date
March 1, 2021
End Date
August 6, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy (absence of disease)
  • Not on any prescribed medications
  • Male and female (in follicular phase)
  • 20-40 years of age
  • Normal BMI range (18.5-24.9)
  • Able to understand and communicate in English
  • Comfortable having blood drawn
  • Willing to provide urine and blood samples
  • Normal urinalysis, Complete Blood Count (CBC) and blood chemistry laboratory test results
  • Willingness to undergo bioimpedance testing, handgrip dynamometry (strength) testing, and pulmonary function test (spirometry).

Exclusion Criteria

  • Glaucoma, Pyloric Stenosis
  • Obstructive Uropathy, Urinary Incontinence
  • Diabetes, Cardiovascular Disease, including Heart Murmurs
  • Diagnosed or with history (last 6 months) and receiving pharma or professional therapy for Psychological/Psychiatric issues
  • Inflammatory conditions, including IBD
  • Subject on any hormone treatment, including thyroid hormone
  • Subject on any steroid therapy including cortisol, or any anti-inflammatory agent
  • Sensitivity to anti-cholinergic drugs
  • Allergic or have sensitivities to rubbing alcohol during blood draw
  • Allergy/sensitivity to any component of the standardized test meal (dextrose, lecithin, soy protein)

Arms & Interventions

Standardized liquid test meal

Intervention: Standardized liquid test meal

Atropine + Standardized liquid Test meal

Intervention: Atropine + Standardized liquid test meal

Outcomes

Primary Outcomes

Time course change in serum glucose

Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

Time course and curve analysis of serum glucose response after the test meal administration with and without atropine pre-treatment.

Time course change in serum insulin

Time Frame: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

Time course and curve analysis of serum insulin response after the test meal administration with and without atropine pre-treatment

Time course change in serum triglycerides

Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

Time course and curve analysis of serum triglycerides response after the test meal administration with and without atropine pre-treatment

Time course change in plasma HISS levels

Time Frame: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

Time course and curve analysis of plasma HISS response after the test meal administration with and without atropine pre-treatment

Secondary Outcomes

  • Time course change in serum free fatty acids(Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration)
  • Time course change in plasma lactate(Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration)
  • Time frame fasted HOMA-IR (Molar Units)(Control: Baseline fasted Test: 15 mins post atropine)
  • Time course change in Meal Induced Glycemia (MIG) scores (Molar Units)(Control: Every 30 minutes up to 4 hours after test meal administration; Test: Every 30 minutes up to 4 hours after test meal administration)

Study Sites (1)

Loading locations...

Similar Trials